{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:48Z","timestamp":1791668868078,"version":"4.3.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019643","name":"Soochow University State Key Laboratory of Radiation Medicine and Protection","doi-asserted-by":"publisher","award":["GZC00401"],"award-info":[{"award-number":["GZC00401"]}],"id":[{"id":"10.13039\/501100019643","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jconrel.2025.113686","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T16:52:15Z","timestamp":1743871935000},"page":"113686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy"],"prefix":"10.1016","volume":"382","author":[{"given":"Juan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.113686_bb0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s41587-024-02295-z","article-title":"Precision radiation opens a new window on cancer therapy","volume":"42","author":"Senior","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0015","first-page":"255","article-title":"Radiotheranostics in oncology: making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jconrel.2025.113686_bb0020","doi-asserted-by":"crossref","first-page":"114538","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2025.113686_bb0025","first-page":"1228","article-title":"Harnessing progress in radiotherapy for global cancer control","volume":"4","author":"Jaffray","year":"2023","journal-title":"Nat. Can."},{"key":"10.1016\/j.jconrel.2025.113686_bb0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.annonc.2023.03.001","article-title":"Next generation radiotheranostics promoting precision medicine","volume":"34","author":"Pomykala","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0040","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0045","doi-asserted-by":"crossref","first-page":"220859","DOI":"10.1148\/radiol.220859","article-title":"177Lu\u2013prostate-specific membrane antigen Radioligand therapy in patients with metastatic castration-resistant prostate Cancer","volume":"306","author":"Parihar","year":"2022","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2025.113686_bb0050","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.2967\/jnumed.123.265546","article-title":"Clinical experience with 225Ac ac-PSMA treatment in patients with 177Lu Lu-PSMA-refractory metastatic castration-resistant prostate cancer","volume":"64","author":"Alan-Selcuk","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0055","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","article-title":"Experience of rescue therapy with177Lu-rhPSMA-10.1 in patients with primary or acquired resistance to 177Lu-PSMA-I&T","volume":"52","author":"Gaeble","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.113686_bb0060","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of Actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate Cancer after failure of Lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0070","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","article-title":"Advances in targeted alpha therapy for prostate cancer","volume":"30","author":"De Vincentis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0075","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jconrel.2024.09.040","article-title":"PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer","volume":"375","author":"Huangfu","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.113686_bb0080","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00259-024-06658-1","article-title":"Advances in targeted alpha therapy of cancer","volume":"51","author":"Sathekge","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.113686_bb0085","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","article-title":"Tumor therapy with targeted atomic Nanogenerators","volume":"294","author":"McDevitt","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2025.113686_bb0090","doi-asserted-by":"crossref","first-page":"118053","DOI":"10.1016\/j.trac.2024.118053","article-title":"Recent advances in emerging radiopharmaceuticals and the challenges in radiochemistry and analytical chemistry","volume":"182","author":"Ding","year":"2025","journal-title":"Trends Anal. Chem."},{"key":"10.1016\/j.jconrel.2025.113686_bb0095","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225-and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2025.113686_bb0100","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","article-title":"A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising lutetium-177 and Actinium-225 in metastatic prostate cancer","volume":"87","author":"Dai","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0105","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2011-04-347039","article-title":"Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model","volume":"118","author":"Pagel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113686_bb0110","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with Gallium-68, Lutetium-177, Copper-64\/67, Actinium-225, and Lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.113686_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0120","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1182\/blood-2019-128678","article-title":"Preclinical development of an Actinium-225-labeled antibody radio-conjugate directed against CD45 for targeted conditioning and radioimmunotherapy","volume":"134","author":"Ludwig","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2025.113686_bb0125","doi-asserted-by":"crossref","first-page":"233408","DOI":"10.1148\/radiol.233408","article-title":"Dotatate PET\/CT and 225Ac-dotatate therapy for somatostatin receptor\u2013expressing metastatic breast cancer","volume":"312","author":"Ulaner","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2025.113686_bb0130","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.semnuclmed.2020.02.003","article-title":"Supply and clinical application of actinium-225 and bismuth-213","volume":"50","author":"Morgenstern","year":"2020","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12943-024-02137-1","article-title":"Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2025.113686_bb0140","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2025.113686_bb0145","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0150","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/ph17081031","article-title":"Future treatment strategies for cancer patients combining targeted alpha therapy with pillars of cancer treatment: external beam radiation therapy, checkpoint inhibition immunotherapy, cytostatic chemotherapy, and brachytherapy","volume":"17","author":"Winter","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2025.113686_bb0155","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41585-024-00924-5","article-title":"Immune effects of \u03b1 and \u03b2 radionuclides in metastatic prostate cancer","volume":"21","author":"Lunj","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0160","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40824-022-00290-6","article-title":"Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy\/chemodynamic therapy to discourage cancer progression","volume":"26","author":"Zhang","year":"2022","journal-title":"Biomater. Res."},{"key":"10.1016\/j.jconrel.2025.113686_bb0165","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2022.08.043","article-title":"Diffusing alpha-emitters radiation therapy promotes a proimmunogenic tumor microenvironment and synergizes with programmed cell death protein 1 blockade","volume":"115","author":"Mare","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.jconrel.2025.113686_bb0170","doi-asserted-by":"crossref","first-page":"122915","DOI":"10.1016\/j.biomaterials.2024.122915","article-title":"Targeting senescence with radioactive 223Ra\/Ba SAzymes enables senolytics-unlocked one-two punch strategy to boost anti-tumor immunotherapy","volume":"315","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2025.113686_bb0175","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3390\/cancers13153676","article-title":"Targeted alpha-particle radiotherapy and immune checkpoint inhibitors induces cooperative inhibition on tumor growth of malignant melanoma","volume":"13","author":"Li","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2025.113686_bb0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.120.251017","article-title":"First clinical results for PSMA-targeted \u03b1-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients","volume":"62","author":"Zacherl","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0185","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","article-title":"Establishing (177)Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer","volume":"58","author":"Fendler","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0190","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-18-1650","article-title":"Leveraging bioorthogonal click chemistry to improve (225)ac-radioimmunotherapy of pancreatic ductal adenocarcinoma","volume":"25","author":"Poty","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113686_bb0195","doi-asserted-by":"crossref","first-page":"231703","DOI":"10.1148\/radiol.231703","article-title":"Emerging theranostics for prostate cancer and a model of prostate-specific membrane antigen therapy","volume":"311","author":"Jewell","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2025.113686_bb0200","first-page":"2703","article-title":"Potential applications for sigma receptor ligands in cancer diagnosis and therapy","volume":"2015","author":"van Waarde","year":"1848","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2025.113686_bb0205","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2005.11.011","article-title":"The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines","volume":"242","author":"Aydar","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2025.113686_bb0210","first-page":"408","article-title":"Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines","volume":"55","author":"Vilner","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.113686_bb0220","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0225","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1021\/jm990141f","article-title":"Improved in vivo stability of actinium-225 macrocyclic complexes","volume":"42","author":"Deal","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2025.113686_bb0230","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.apradiso.2013.12.008","article-title":"Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles","volume":"85","author":"Wang","year":"2014","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jconrel.2025.113686_bb0235","doi-asserted-by":"crossref","first-page":"214130","DOI":"10.1016\/j.ccr.2021.214130","article-title":"The coordination properties and ionic radius of actinium: a 120-year-old enigma","volume":"446","author":"Deblonde","year":"2021","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.jconrel.2025.113686_bb0240","doi-asserted-by":"crossref","first-page":"954925","DOI":"10.4161\/21624011.2014.954925","article-title":"Using \u03b1 radiation to boost cancer immunity?","volume":"3","author":"Gorin","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jconrel.2025.113686_bb0250","doi-asserted-by":"crossref","first-page":"2401438","DOI":"10.1002\/adhm.202401438","article-title":"Imageable brachytherapy with Chelator-free radiolabeling hydrogel","volume":"13","author":"Cui","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.jconrel.2025.113686_bb0255","doi-asserted-by":"crossref","first-page":"2307448","DOI":"10.1002\/smll.202307448","article-title":"Alpha-emitter radium-223 induces STING-dependent pyroptosis to trigger robust antitumor immunity","volume":"20","author":"Yang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2025.113686_bb0260","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/acs.molpharmaceut.3c00427","article-title":"Effective treatment of SSTR2-positive small cell lung cancer using 211At-containing targeted \u03b1-particle therapy agent which promotes endogenous antitumor immune response","volume":"20","author":"Qin","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2025.113686_bb0265","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neo.2014.04.002","article-title":"Antitumor immunity induced after \u03b1 irradiation","volume":"16","author":"Gorin","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.jconrel.2025.113686_bb0270","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade enhances (225)ac-PSMA617 efficacy in a mouse model of prostate Cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0275","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.0c00206","article-title":"PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma","volume":"4","author":"Dabagian","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2025.113686_bb0280","doi-asserted-by":"crossref","first-page":"29439","DOI":"10.1021\/acsnano.3c12337","article-title":"Robust and sustained STING pathway activation via hydrogel-based in situ vaccination for Cancer immunotherapy","volume":"18","author":"Cheng","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.113686_bb0285","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113686_bb0290","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2025.113686_bb0295","doi-asserted-by":"crossref","first-page":"eabb3631","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0300","doi-asserted-by":"crossref","first-page":"7948","DOI":"10.7150\/thno.39203","article-title":"Integrin \u03b1v\u03b23-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy","volume":"9","author":"Chen","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2025.113686_bb0305","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2967\/jnumed.118.209510","article-title":"Combined VLA-4-targeted radionuclide therapy and immunotherapy in a mouse model of melanoma","volume":"59","author":"Choi","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2025.113686_bb0310","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2025.113686_bb0315","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0320","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","article-title":"Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases","volume":"34","author":"Kasoha","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jconrel.2025.113686_bb0325","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.3748\/wjg.v26.i48.7664","article-title":"Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis","volume":"26","author":"Chen","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2025.113686_bb0330","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925003062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:34Z","timestamp":1777870414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925003062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":64,"alternative-id":["S0168365925003062"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113686","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-targeted alpha therapy mitigates prostate cancer and boosts immune checkpoint blockade therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.113686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113686"}}